Sani Uba
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sani Uba has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Adamu Uzairu
Department of Chemistry, Faculty of Physical Sciences, Ahmadu Bello University, Zaria, Nigeria
7 shared publications - Gideon Adamu Shallangwa
Ahmadu Bello University
4 shared publications - Hadiza Lawal Abdulrahman
Department of Chemistry, Ahmadu Bello University, Zaria, Nigeria
3 shared publications - Abdullahi Bello Umar
College of Materials Engineering Fujian Agriculture and Forestry University Fuzhou People's Republic of China
2 shared publications - Muhammad Tukur Ibrahim
Ahmadu Bello University
2 shared publications - Abdullahi Bello Umar
Department of Chemistry, Faculty of Physical Sciences, Ahmad Bello University, Zaria, Kaduna State, Nigeria
1 shared publication
Latest Publications
- Open Access
- 14 October 2025
- Published by African Journals Online (AJOL) in Communication in Physical Sciences
- Vol. 12 (3) , 823-833
Risk assessment of selected metallic pollutants in fish from Zuru dam, Kebbi State, Nigeria
This study investigates the concentration of metallic pollutants in fish samples from Zuru Dam and assesses the potential health risks associated with consuming these fish. Six fish samples, comprising three catfish and three tilapia, were collected from local fishermen. The concentration of metals, including iron (Fe), zinc (Zn), copper (Cu), chromium (Cr), cobalt (Co), lead (Pb), and potassium (K), was analyzed using the Atomic Absorption Spectrometric (AAS) technique. The results showed varying concentrations of Fe, Zn, and Cu, with Fe levels ranging from 7.85 ± 0.21 (CF2) to 128.5 ± 9.19 (TG3), Zn ranging from 8.75 ± 0.25 (CF2) to 42.321 ± 0.11 (CG1), and Cu found to be below detection limits (BDL) in several samples. The concentration of Cr, Co, Pb, and K also varied, with some samples showing detectable levels of these metals. Comparison with World Health Organization (WHO) tolerance limits revealed that Fe and Zn concentrations exceeded the acceptable limits, while Cu and K were well below their respective limits. Chromium and cobalt concentrations were within the WHO limits, except for a few samples, while Pb was only detected in TG1. The analysis showed significant differences (P < 0.05) in the concentrations of Cu, Cr, and Pb, indicating distinct pollution sources for these metals. Health risk assessment based on the Hazard Index (HI) indicated that adult consumers of certain fish samples, such as TG3, CG3, CG1, CG2, CF2, TG1, and TF1, may be at high risk of health problems due to the contamination, with HI values greater than 5. For children, HI values exceeding 1 in some samples suggested moderate health risks, particularly in TF2, TG1, CG1, and CG3. This study highlights the presence of significant heavy metal contamination in fish from Zuru Dam, posing health risks to consumers, particularly children and adults who consume high-risk samples. The findings underscore the need for regular monitoring of metal concentrations in the region and the implementation of pollution control measures. Public awareness programs should be initiated to inform local populations about the potential health risks associated with consuming contaminated fish, especially for vulnerable groups such as children. Further research is recommended to identify the specific sources of contamination and the long-term impacts on the aquatic ecosystem and human health.
- 14 October 2025
- Published by African Journals Online (AJOL) in Communication in Physical Sciences
- Vol. 12 (3) , 823-833
Open AccessRisk assessment of selected metallic pollutants in fish from Zuru dam, Kebbi State, Nigeria
This study investigates the concentration of metallic pollutants in fish samples from Zuru Dam and assesses the potential health risks associated with consuming these fish. Six fish samples, comprising three catfish and three tilapia, were collected from local fishermen. The concentration of metals, including iron (Fe), zinc (Zn), copper (Cu), chromium (Cr), cobalt (Co), lead (Pb), and potassium (K), was analyzed using the Atomic Absorption Spectrometric (AAS) technique. The results showed varying concentrations of Fe, Zn, and Cu, with Fe levels ranging from 7.85 ± 0.21 (CF2) to 128.5 ± 9.19 (TG3), Zn ranging from 8.75 ± 0.25 (CF2) to 42.321 ± 0.11 (CG1), and Cu found to be below detection limits (BDL) in several samples. The concentration of Cr, Co, Pb, and K also varied, with some samples showing detectable levels of these metals. Comparison with World Health Organization (WHO) tolerance limits revealed that Fe and Zn concentrations exceeded the acceptable limits, while Cu and K were well below their respective limits. Chromium and cobalt concentrations were within the WHO limits, except for a few samples, while Pb was only detected in TG1. The analysis showed significant differences (P < 0.05) in the concentrations of Cu, Cr, and Pb, indicating distinct pollution sources for these metals. Health risk assessment based on the Hazard Index (HI) indicated that adult consumers of certain fish samples, such as TG3, CG3, CG1, CG2, CF2, TG1, and TF1, may be at high risk of health problems due to the contamination, with HI values greater than 5. For children, HI values exceeding 1 in some samples suggested moderate health risks, particularly in TF2, TG1, CG1, and CG3. This study highlights the presence of significant heavy metal contamination in fish from Zuru Dam, posing health risks to consumers, particularly children and adults who consume high-risk samples. The findings underscore the need for regular monitoring of metal concentrations in the region and the implementation of pollution control measures. Public awareness programs should be initiated to inform local populations about the potential health risks associated with consuming contaminated fish, especially for vulnerable groups such as children. Further research is recommended to identify the specific sources of contamination and the long-term impacts on the aquatic ecosystem and human health.
- Open Access
- 14 March 2025
- Published by Springer Nature in Research Square
Ligand-based design of potent Dipeptidyl Peptidase-IV (DPP-IV) inhibitors in heterocyclic compounds using QSAR, docking, ADMET, and pharmacological profiling for anti-diabetic potential.
ABSTRACT Type 2 Diabetes Mellitus (T2DM) is characterized by high glucose levels in the blood and impaired insulin function, often leading to complications like visual impairment, amputation, and nephropathy. It is a global health challenge and is projected to become the seventh leading cause of mortality. This research aimed to design effective and safer Dipeptidyl Peptidase-IV (DPP-IV) inhibitors as potential T2DM treatments. Five QSAR models were developed, the third model was the most robust, with R² = 0.9904, Q²cv = 0.9836, and R²pred = 0.8989. Based on this model, the newly designed compounds, yielding pIC50 values range 8.1015–8.2760, better than the template (pIC50=8.0), and the reference drug Sitagliptin (pIC50). Docking studies revealed better binding affinities for the newly designed compounds. These compounds exhibited non-harmful profiles and good pharmacokinetics. Using Material Studio v8.0, a Quantitative structure-activity relationship (QSAR) model was constructed and validated through both internal and external assessment procedures. Virtual screening identified a template compound that underwent structural modifications to enhance efficacy. Molecular docking studies using Protein Data Bank data (PDB ID: 3c59) pinpointed active site residues. The pharmacological characteristics of the compounds were evaluated using ADMETlab, SwissADME, and pKCSM. The findings suggest the designed DDP-IV inhibitors are potential candidates for T2DM treatment, giving better results and safety compared to the template and reference drug (Sitagliptin) used in this study. Keywords QSAR, Type 2 Diabetes Mellitus (T2DM), Ligand-based design, Heterocyclic derivatives, Dipeptidyl Peptidase-IV (DPP-IV) inhibitors, Molecular docking, ADMET, and Pharmacokinetic profiling
- 14 March 2025
- Published by Springer Nature in Research Square
Open AccessLigand-based design of potent Dipeptidyl Peptidase-IV (DPP-IV) inhibitors in heterocyclic compounds using QSAR, docking, ADMET, and pharmacological profiling for anti-diabetic potential.
ABSTRACT Type 2 Diabetes Mellitus (T2DM) is characterized by high glucose levels in the blood and impaired insulin function, often leading to complications like visual impairment, amputation, and nephropathy. It is a global health challenge and is projected to become the seventh leading cause of mortality. This research aimed to design effective and safer Dipeptidyl Peptidase-IV (DPP-IV) inhibitors as potential T2DM treatments. Five QSAR models were developed, the third model was the most robust, with R² = 0.9904, Q²cv = 0.9836, and R²pred = 0.8989. Based on this model, the newly designed compounds, yielding pIC50 values range 8.1015–8.2760, better than the template (pIC50=8.0), and the reference drug Sitagliptin (pIC50). Docking studies revealed better binding affinities for the newly designed compounds. These compounds exhibited non-harmful profiles and good pharmacokinetics. Using Material Studio v8.0, a Quantitative structure-activity relationship (QSAR) model was constructed and validated through both internal and external assessment procedures. Virtual screening identified a template compound that underwent structural modifications to enhance efficacy. Molecular docking studies using Protein Data Bank data (PDB ID: 3c59) pinpointed active site residues. The pharmacological characteristics of the compounds were evaluated using ADMETlab, SwissADME, and pKCSM. The findings suggest the designed DDP-IV inhibitors are potential candidates for T2DM treatment, giving better results and safety compared to the template and reference drug (Sitagliptin) used in this study. Keywords QSAR, Type 2 Diabetes Mellitus (T2DM), Ligand-based design, Heterocyclic derivatives, Dipeptidyl Peptidase-IV (DPP-IV) inhibitors, Molecular docking, ADMET, and Pharmacokinetic profiling
- Open Access
- 12 March 2025
- Published by Springer Nature in Research Square
Leveraging In-silico Methods for Laryngeal Cancer Drug Discovery Utilizing QSAR, ligand-base Design, Molecular Docking, and Pharmacokinetic Profiling Approaches.
Objective: This study investigated the design and evaluation of new and more active anti-cancer compounds targeting laryngeal carcinoma Methods: In this study, quantitative structure-activity relationship modeling, ligand-based drug design, molecular docking, and pharmacokinetic studies were utilized in carrying out this research. Result and conclusion: A robust QSAR model was developed, achieving R2adj of 0.8257, R2 of 0.8872 and R²pred of 0.6997, which indicated a reliable predictive capability where the model parameters EE_Dzm and SpAD_DzZ were used in designing five new compounds with compound 3C identified as the most promising candidate, exhibiting a Moldock score of -98.973kcalmol−1, re-rank score of -69.093 kcalmol−1 , predicted activity of 5.349 and a total energy of atoms measured at -64.4248 kcalmol−1, indicating strong binding affinity better than the template 10l and the standard drug. Most importantly, all the five designed compounds adhered to Lipinski's Rule of Five and passed drug-likeness tests, indicating favorable pharmacokinetic profiles.
- 12 March 2025
- Published by Springer Nature in Research Square
Open AccessLeveraging In-silico Methods for Laryngeal Cancer Drug Discovery Utilizing QSAR, ligand-base Design, Molecular Docking, and Pharmacokinetic Profiling Approaches.
Objective: This study investigated the design and evaluation of new and more active anti-cancer compounds targeting laryngeal carcinoma Methods: In this study, quantitative structure-activity relationship modeling, ligand-based drug design, molecular docking, and pharmacokinetic studies were utilized in carrying out this research. Result and conclusion: A robust QSAR model was developed, achieving R2adj of 0.8257, R2 of 0.8872 and R²pred of 0.6997, which indicated a reliable predictive capability where the model parameters EE_Dzm and SpAD_DzZ were used in designing five new compounds with compound 3C identified as the most promising candidate, exhibiting a Moldock score of -98.973kcalmol−1, re-rank score of -69.093 kcalmol−1 , predicted activity of 5.349 and a total energy of atoms measured at -64.4248 kcalmol−1, indicating strong binding affinity better than the template 10l and the standard drug. Most importantly, all the five designed compounds adhered to Lipinski's Rule of Five and passed drug-likeness tests, indicating favorable pharmacokinetic profiles.
- 28 December 2022
- Published by Springer Nature in Chemistry Africa
- Vol. 6 (3) , 1561-1577
Terminalia catappa as Effective Corrosion Resistance in Acidic Medium for Medical Stainless Steel via Experimental and Computational Approaches
- 28 December 2022
- Published by Springer Nature in Chemistry Africa
- Vol. 6 (3) , 1561-1577
Terminalia catappa as Effective Corrosion Resistance in Acidic Medium for Medical Stainless Steel via Experimental and Computational Approaches
- Open Access
- 29 November 2020
- Published by Springer Nature in Chemistry Africa
- Vol. 4 (1) , 175-187
QSAR, Ligand Based Design and Pharmacokinetic Studies of Parviflorons Derivatives as Anti-Breast Cancer Drug Compounds Against MCF-7 Cell Line
The anti-proliferative activities of Novel series of Parviflorons against MCF-7 breast cancer cell line was explored via in-silico studies like Quantitative Structure–Activity Relationship QSAR, designing new compounds and analyzing the pharmacokinetics properties of the designed compounds. From QSAR, model one emerged the best from the statistical assessments of (R2) = 0.9444, (R2adj) = 0.9273, (Q2) = 0.8945 and (R2pred) of 0.6214. The model was used in designing new derivative compounds, with higher effectiveness against estrogen positive breast cancer (MCF-7). The pharmacokinetics analysis carried out on the newly designed compounds showed that all the compounds passed the drug-likeness test and also the Lipinski rule of five, and they could further proceed to pre-clinical tests. The results indicates that the derivative compounds would serve as potent cure to estrogen positive breast cancer (MCF-7 cell line).
- 29 November 2020
- Published by Springer Nature in Chemistry Africa
- Vol. 4 (1) , 175-187
Open AccessQSAR, Ligand Based Design and Pharmacokinetic Studies of Parviflorons Derivatives as Anti-Breast Cancer Drug Compounds Against MCF-7 Cell Line
The anti-proliferative activities of Novel series of Parviflorons against MCF-7 breast cancer cell line was explored via in-silico studies like Quantitative Structure–Activity Relationship QSAR, designing new compounds and analyzing the pharmacokinetics properties of the designed compounds. From QSAR, model one emerged the best from the statistical assessments of (R2) = 0.9444, (R2adj) = 0.9273, (Q2) = 0.8945 and (R2pred) of 0.6214. The model was used in designing new derivative compounds, with higher effectiveness against estrogen positive breast cancer (MCF-7). The pharmacokinetics analysis carried out on the newly designed compounds showed that all the compounds passed the drug-likeness test and also the Lipinski rule of five, and they could further proceed to pre-clinical tests. The results indicates that the derivative compounds would serve as potent cure to estrogen positive breast cancer (MCF-7 cell line).
- Open Access
- 27 November 2020
- Published by Springer Nature in Journal of Bioenergetics and Biomembranes
- Vol. 52 (6) , 475-494
QSAR, molecular docking, design, and pharmacokinetic analysis of 2-(4-fluorophenyl) imidazol-5-ones as anti-breast cancer drug compounds against MCF-7 cell line
The anti-proliferative activities of Novel series of 2-(4-fluorophenyl) imidazol-5-ones against MCF-7 breast cancer cell line were explored via in-slico studies which includes Quantitative structure–activity relationship QSAR, molecular docking studies, designing new compounds, and analyzing the pharmacokinetics properties of the designed compounds. From the QSAR analysis, model number one emerged the best as seen from the arithmetic assessments of (R2) = 0.6981, (R2adj) = 0.6433, (Q2) = 0.5460 and (R2pred) of 0.5357. Model number one was used in designing new derivative compounds, with higher effectiveness against estrogen positive breast cancer (MCF-7 cell line). The Molecular docking studies between the derivatives and Polo-like kinases (Plk1) receptor proved that the derivatives of 2-(4-fluorophenyl) imidazol-5-ones bind tightly to the receptor, thou ligand 24 and 27 had the highest binding affinities of −8.8 and − 9.1 kcal/mol, which was found to be higher than Doxorubicin with a docking score of −8.0 kcal/mol. These new derivatives of 2-(4-fluorophenyl) imidazol-5-ones shall be excellent inhibitors against (plk1). The pharmacokinetics analysis performed on the new structures revealed that all the structures passed the test and also the Lipinski rule of five, and they could further proceed to pre-clinical tests. They both revealed a revolution in medicine for developing novel anti-breast cancer drugs against MCF-7 cell line.
- 27 November 2020
- Published by Springer Nature in Journal of Bioenergetics and Biomembranes
- Vol. 52 (6) , 475-494
Open AccessQSAR, molecular docking, design, and pharmacokinetic analysis of 2-(4-fluorophenyl) imidazol-5-ones as anti-breast cancer drug compounds against MCF-7 cell line
The anti-proliferative activities of Novel series of 2-(4-fluorophenyl) imidazol-5-ones against MCF-7 breast cancer cell line were explored via in-slico studies which includes Quantitative structure–activity relationship QSAR, molecular docking studies, designing new compounds, and analyzing the pharmacokinetics properties of the designed compounds. From the QSAR analysis, model number one emerged the best as seen from the arithmetic assessments of (R2) = 0.6981, (R2adj) = 0.6433, (Q2) = 0.5460 and (R2pred) of 0.5357. Model number one was used in designing new derivative compounds, with higher effectiveness against estrogen positive breast cancer (MCF-7 cell line). The Molecular docking studies between the derivatives and Polo-like kinases (Plk1) receptor proved that the derivatives of 2-(4-fluorophenyl) imidazol-5-ones bind tightly to the receptor, thou ligand 24 and 27 had the highest binding affinities of −8.8 and − 9.1 kcal/mol, which was found to be higher than Doxorubicin with a docking score of −8.0 kcal/mol. These new derivatives of 2-(4-fluorophenyl) imidazol-5-ones shall be excellent inhibitors against (plk1). The pharmacokinetics analysis performed on the new structures revealed that all the structures passed the test and also the Lipinski rule of five, and they could further proceed to pre-clinical tests. They both revealed a revolution in medicine for developing novel anti-breast cancer drugs against MCF-7 cell line.
- Open Access
- 11 November 2020
- Published by Springer Nature in Chemistry Africa
- Vol. 4 (1) , 189-205
Molecular Docking Strategy to Design Novel V600E-BRAF Kinase Inhibitors with Prediction of Their Drug-Likeness and Pharmacokinetics ADMET Properties
- 11 November 2020
- Published by Springer Nature in Chemistry Africa
- Vol. 4 (1) , 189-205
Open AccessMolecular Docking Strategy to Design Novel V600E-BRAF Kinase Inhibitors with Prediction of Their Drug-Likeness and Pharmacokinetics ADMET Properties
- 18 September 2020
- Published by Springer Nature in Chemistry Africa
- Vol. 3 (4) , 1009-1022
QSAR and Docking Studies on Some Potential Anti-Cancer Agents to Predict their Effect on M14 Melanoma Cell Line
- 18 September 2020
- Published by Springer Nature in Chemistry Africa
- Vol. 3 (4) , 1009-1022
QSAR and Docking Studies on Some Potential Anti-Cancer Agents to Predict their Effect on M14 Melanoma Cell Line
- Open Access
- 15 September 2020
- Published by Springer Nature in Structural Chemistry
- Vol. 32 (2) , 679-687
Computer modeling of some anti-breast cancer compounds
The research was aimed at exploring the biological activities of novel series of β-lactam derivatives against MCF-7 breast cancer cell lines via computer modeling such as quantitative structure-activity relationship (QSAR), designing new compounds and analyzing the drug likeliness of designed compounds. The QSAR model was highly robust as it also conforms to the least minimum requirement for QSAR model from the statistical assessments with a correlation coefficient squared (R2) of 0.8706, correlation coefficient adjusted squared (R2adj) of 0.8411, and cross-validation coefficient (Q2) of 0.7844. The external validation ofR2predwas calculated as 0.6083 for model 4. The model parameters (MATS5i and MATS1s) were used in designing new derivative compounds with higher potency against estrogen-positive breast cancer. The pharmacokinetics test on the restructured compounds revealed that all the compounds passed the drug likeness test and they could further proceed to clinical trials. These reveal a breakthrough in medicine, in the research for breast cancer drug with higher effectiveness against the MCF-7 cell line.
- 15 September 2020
- Published by Springer Nature in Structural Chemistry
- Vol. 32 (2) , 679-687
Open AccessComputer modeling of some anti-breast cancer compounds
The research was aimed at exploring the biological activities of novel series of β-lactam derivatives against MCF-7 breast cancer cell lines via computer modeling such as quantitative structure-activity relationship (QSAR), designing new compounds and analyzing the drug likeliness of designed compounds. The QSAR model was highly robust as it also conforms to the least minimum requirement for QSAR model from the statistical assessments with a correlation coefficient squared (R2) of 0.8706, correlation coefficient adjusted squared (R2adj) of 0.8411, and cross-validation coefficient (Q2) of 0.7844. The external validation ofR2predwas calculated as 0.6083 for model 4. The model parameters (MATS5i and MATS1s) were used in designing new derivative compounds with higher potency against estrogen-positive breast cancer. The pharmacokinetics test on the restructured compounds revealed that all the compounds passed the drug likeness test and they could further proceed to clinical trials. These reveal a breakthrough in medicine, in the research for breast cancer drug with higher effectiveness against the MCF-7 cell line.
- Open Access
- 11 October 2018
- Published by Scientific Scholar in Journal of King Saud University – Science
- Vol. 32 (1) , 657-666
Molecular docking and quantitative structure-activity relationship study of anti-ulcer activity of quinazolinone derivatives
Proton pump inhibitors portray the first choice for treating various ulcer diseases because it inhibits H+/K+-ATPase enzyme, by covalently binding to a cysteine residue of either potassium or proton pump, therefore this enzyme is a validated target for anti-ulcer drugs. A Quantitative structure-affinity relationship (QSAR) and molecular docking analysis were carryout on 30 quinazolinone derivatives as H+/K+-ATPase inhibitors. QSAR study was performed using Material studio software version 8.0, while molecular docking analysis of all the novel quinazolinone derivatives was performed using Autodock vina version 4.0 of Pyrx software. The QSAR result reveal a strong correlation value of R2 = 0.9131, R2adj = 0.8914, Q2LOO = 0.8038 and R2 pred = 0.8946 which showed a highly predictive and statistically significant model. Molecular docking analysis revealed that the ligand 25 bind tightly deep to H+/K+-ATPase (protein target). Because of the high binding affinity of −9.3 kcal/mol. This research has revealed a significant correlation between binding score and biological activities of the molecules, and the results are even better than the one proposed by other authors, more also, both results of quantitative structure-affinity relationship (QSAR) and docking studies agree with each other which give chance for design and synthesis of novel anti-ulcer agents exhibiting good action against the receptor (H+/K+-ATPase) Furthermore, the present study prove more potent drugs than the ones already marketed.
- 11 October 2018
- Published by Scientific Scholar in Journal of King Saud University – Science
- Vol. 32 (1) , 657-666
Open AccessMolecular docking and quantitative structure-activity relationship study of anti-ulcer activity of quinazolinone derivatives
Proton pump inhibitors portray the first choice for treating various ulcer diseases because it inhibits H+/K+-ATPase enzyme, by covalently binding to a cysteine residue of either potassium or proton pump, therefore this enzyme is a validated target for anti-ulcer drugs. A Quantitative structure-affinity relationship (QSAR) and molecular docking analysis were carryout on 30 quinazolinone derivatives as H+/K+-ATPase inhibitors. QSAR study was performed using Material studio software version 8.0, while molecular docking analysis of all the novel quinazolinone derivatives was performed using Autodock vina version 4.0 of Pyrx software. The QSAR result reveal a strong correlation value of R2 = 0.9131, R2adj = 0.8914, Q2LOO = 0.8038 and R2 pred = 0.8946 which showed a highly predictive and statistically significant model. Molecular docking analysis revealed that the ligand 25 bind tightly deep to H+/K+-ATPase (protein target). Because of the high binding affinity of −9.3 kcal/mol. This research has revealed a significant correlation between binding score and biological activities of the molecules, and the results are even better than the one proposed by other authors, more also, both results of quantitative structure-affinity relationship (QSAR) and docking studies agree with each other which give chance for design and synthesis of novel anti-ulcer agents exhibiting good action against the receptor (H+/K+-ATPase) Furthermore, the present study prove more potent drugs than the ones already marketed.